1.On Ryokyu ARIMA, Tenmin NAMIKAWA's Mentor
Takanori MATSUOKA ; Hideki KURIBAYASHI ; Masashi BEPPU ; Hidetoshi YAMAGUCHI ; Hideyuki NAKATA ; Tamie ANAN ; Tsukasa FUEKI ; Kenju RAI ; Hidetoshi ITAKURA ; Koichiro TANAKA ; Yoshinari KONO ; Mikumo UEMATSU ; Kazuhiko NARA ; Keiko SERIZAWA ; Kenkichi OKADA ; Yusen IWAI ; Kazuhiro MAKIZUMI ; Oto MIURA ; Takao NAMIKI ; Tetsuo AKIBA
Kampo Medicine 2012;63(6):417-427
Tenmin NAMIKAWA (並河天民) thought the Shanghanlun (傷寒論) was an important text. He also taught his pupils the importance of prescribing Zhongjing ZHANG's (張仲景) medicines. Ryokyu ARIMA (有馬凉及) was a physician-teacher, who prescribed Chengqitang (承気湯) for the emperor without conferring with other doctors. His chengqitang formulary was derived from medical texts by Zhongjing ZHANG. Kyugo GODA (合田求吾) on the other hand, was a pupil of Ikkannsai MATSUBARA (松原一閑斎), who wrote in the Idokikigaki (医道聞書) : theKoho (古方) school started by Ryokyu ARIMA. He was a hero who was punished by the Goseiin (後西院) emperor. He taught Koho to Tenmin. This therefore reveals that Ryokyu ARIMA was a teacher who taught the importance of the Shanghanlun.
2.Diagnostic value of homogenous delayed enhancement in contrast-enhanced computed tomography images and endoscopic ultrasound-guided tissue acquisition for patients with focal autoimmune pancreatitis
Keisuke YONAMINE ; Shinsuke KOSHITA ; Yoshihide KANNO ; Takahisa OGAWA ; Hiroaki KUSUNOSE ; Toshitaka SAKAI ; Kazuaki MIYAMOTO ; Fumisato KOZAKAI ; Hideyuki ANAN ; Haruka OKANO ; Masaya OIKAWA ; Takashi TSUCHIYA ; Takashi SAWAI ; Yutaka NODA ; Kei ITO
Clinical Endoscopy 2023;56(4):510-520
Background/Aims:
We aimed to investigate (1) promising clinical findings for the recognition of focal type autoimmune pancreatitis (FAIP) and (2) the impact of endoscopic ultrasound (EUS)-guided tissue acquisition (EUS-TA) on the diagnosis of FAIP.
Methods:
Twenty-three patients with FAIP were involved in this study, and 44 patients with resected pancreatic ductal adenocarcinoma (PDAC) were included in the control group.
Results:
(1) Multivariate analysis revealed that homogeneous delayed enhancement on contrast-enhanced computed tomography was a significant factor indicative of FAIP compared to PDAC (90% vs. 7%, p=0.015). (2) For 13 of 17 FAIP patients (76.5%) who underwent EUS-TA, EUS-TA aided the diagnostic confirmation of AIPs, and only one patient (5.9%) was found to have AIP after surgery. On the other hand, of the six patients who did not undergo EUS-TA, three (50.0%) underwent surgery for pancreatic lesions.
Conclusions
Homogeneous delayed enhancement on contrast-enhanced computed tomography was the most useful clinical factor for discriminating FAIPs from PDACs. EUS-TA is mandatory for diagnostic confirmation of FAIP lesions and can contribute to a reduction in the rate of unnecessary surgery for patients with FAIP.
3.Pancreatic duct lavage cytology combined with a cell-block method for patients with possible pancreatic ductal adenocarcinomas, including pancreatic carcinoma in situ
Hiroaki KUSUNOSE ; Shinsuke KOSHITA ; Yoshihide KANNO ; Takahisa OGAWA ; Toshitaka SAKAI ; Keisuke YONAMINE ; Kazuaki MIYAMOTO ; Fumisato KOZAKAI ; Hideyuki ANAN ; Kazuki ENDO ; Haruka OKANO ; Masaya OIKAWA ; Takashi TSUCHIYA ; Takashi SAWAI ; Yutaka NODA ; Kei ITO
Clinical Endoscopy 2023;56(3):353-366
Background/Aims:
This study aimed to clarify the efficacy and safety of pancreatic duct lavage cytology combined with a cell-block method (PLC-CB) for possible pancreatic ductal adenocarcinomas (PDACs).
Methods:
This study included 41 patients with suspected PDACs who underwent PLC-CB mainly because they were unfit for undergoing endoscopic ultrasonography-guided fine needle aspiration. A 6-Fr double lumen catheter was mainly used to perform PLC-CB. Final diagnoses were obtained from the findings of resected specimens or clinical outcomes during surveillance after PLC-CB.
Results:
Histocytological evaluations using PLC-CB were performed in 87.8% (36/41) of the patients. For 31 of the 36 patients, final diagnoses (invasive PDAC, 12; pancreatic carcinoma in situ, 5; benignancy, 14) were made, and the remaining five patients were excluded due to lack of surveillance periods after PLC-CB. For 31 patients, the sensitivity, specificity, and accuracy of PLC-CB for detecting malignancy were 94.1%, 100%, and 96.8%, respectively. In addition, they were 87.5%, 100%, and 94.1%, respectively, in 17 patients without pancreatic masses detectable using endoscopic ultrasonography. Four patients developed postprocedural pancreatitis, which improved with conservative therapy.
Conclusions
PLC-CB has an excellent ability to detect malignancies in patients with possible PDACs, including pancreatic carcinoma in situ.